CL2021000343A1 - Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) - Google Patents
Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)Info
- Publication number
- CL2021000343A1 CL2021000343A1 CL2021000343A CL2021000343A CL2021000343A1 CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1 CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1
- Authority
- CL
- Chile
- Prior art keywords
- interleukin
- peptide inhibitors
- divisional application
- receptor peptide
- receptor
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 que se pueden utilizar para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatorias.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000343A1 true CL2021000343A1 (es) | 2021-08-06 |
Family
ID=57757647
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000128A CL2018000128A1 (es) | 2015-07-15 | 2018-01-15 | Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias |
| CL2018003322A CL2018003322A1 (es) | 2015-07-15 | 2018-11-22 | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) |
| CL2021000343A CL2021000343A1 (es) | 2015-07-15 | 2021-02-09 | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000128A CL2018000128A1 (es) | 2015-07-15 | 2018-01-15 | Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias |
| CL2018003322A CL2018003322A1 (es) | 2015-07-15 | 2018-11-22 | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (es) |
| JP (1) | JP6858174B2 (es) |
| KR (1) | KR102513978B1 (es) |
| CN (1) | CN108348580B (es) |
| AU (1) | AU2016293619B2 (es) |
| BR (1) | BR112018000691A2 (es) |
| CA (1) | CA2991984A1 (es) |
| CL (3) | CL2018000128A1 (es) |
| CO (1) | CO2018000349A2 (es) |
| CR (1) | CR20180029A (es) |
| DO (1) | DOP2018000010A (es) |
| EA (1) | EA035733B9 (es) |
| EC (1) | ECSP18002929A (es) |
| HK (1) | HK1257747A1 (es) |
| IL (1) | IL256827A (es) |
| MX (1) | MX384213B (es) |
| NI (1) | NI201800008A (es) |
| PE (1) | PE20180571A1 (es) |
| PH (1) | PH12018500086A1 (es) |
| SG (1) | SG10201912066SA (es) |
| SV (1) | SV2018005614A (es) |
| UA (1) | UA123772C2 (es) |
| WO (1) | WO2017011820A2 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618003T3 (es) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corporation | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9822157B2 (en) | 2013-03-15 | 2017-11-21 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| PT2986610T (pt) | 2013-04-19 | 2018-03-09 | Incyte Holdings Corp | Heterociclos bicíclicos como inibidores de fgfr |
| PL3143037T3 (pl) | 2014-05-16 | 2022-01-31 | Protagonist Therapeutics, Inc. | Peptydy tioeterowe - antagoniści integryny alfa-4-beta-7 |
| EP3169403B9 (en) | 2014-07-17 | 2024-07-03 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| KR102632018B1 (ko) | 2015-02-20 | 2024-02-02 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서의 이환식 복소환 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| CA3049889A1 (en) | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
| US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| JP7670605B2 (ja) * | 2018-07-12 | 2025-04-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110015978B (zh) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法 |
| CN114269323B (zh) * | 2019-07-01 | 2024-07-26 | 瓦利托尔有限公司 | 多价肽缀合物的亲水性接头 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3997105A4 (en) * | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| JP2023511551A (ja) | 2020-01-15 | 2023-03-20 | ヤンセン バイオテツク，インコーポレーテツド | インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| CN118027153A (zh) * | 2020-01-15 | 2024-05-14 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20230357323A1 (en) * | 2020-06-29 | 2023-11-09 | University Of Washington | Human il23 receptor binding polypeptides |
| JP2023542867A (ja) | 2020-09-11 | 2023-10-12 | グリンプス バイオ， インコーポレイテッド | 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出 |
| MX2023005994A (es) * | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23. |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| KR20240034223A (ko) * | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제 |
| CN117999274A (zh) * | 2021-07-14 | 2024-05-07 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂 |
| CN118354781A (zh) | 2021-12-01 | 2024-07-16 | 西兰制药公司 | 白介素-23受体的肽抑制剂 |
| US20250223627A1 (en) * | 2022-03-09 | 2025-07-10 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (zh) * | 2022-03-17 | 2023-11-07 | 北京大学 | 订书肽、其制备方法及其制药用途 |
| IL317902A (en) | 2022-06-30 | 2025-02-01 | Sanofi Sa | New peptides as selective antagonists of the IL-23 receptor |
| EP4622991A2 (en) * | 2022-11-21 | 2025-10-01 | Janssen Pharmaceutica NV | Synthesis of a cyclic peptide |
| WO2024155547A2 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| IL322423A (en) | 2023-01-31 | 2025-09-01 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor |
| WO2024227437A1 (zh) * | 2023-05-04 | 2024-11-07 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂制备及其用途 |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2025051920A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2025051912A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| JP2011501941A (ja) * | 2007-07-06 | 2011-01-20 | バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ | Ｉｌ−２３レセプターのアンタゴニストおよびその使用 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) * | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| EP3065757A4 (en) * | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| EP3169403B9 (en) * | 2014-07-17 | 2024-07-03 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/ko active Active
- 2016-07-15 MX MX2018000542A patent/MX384213B/es unknown
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en not_active Withdrawn
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/es unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/ja active Active
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 EA EA201890325A patent/EA035733B9/ru not_active IP Right Cessation
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 CR CR20180029A patent/CR20180029A/es unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en not_active Application Discontinuation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 HK HK19100122.0A patent/HK1257747A1/zh unknown
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/zh active Active
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/pt not_active IP Right Cessation
- 2016-07-15 UA UAA201801482A patent/UA123772C2/uk unknown
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/es unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/es unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/es unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/es unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/es unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/es unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/es unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| CY1122467T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CO2017013446A2 (es) | Composiciones que comprenden cepas bacterianas del género bacteroides | |
| CL2018001368A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2017003142A1 (es) | Composiciones que comprenden cepas bacterianas | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
| MX2018006240A (es) | Composiciones que comprenden cepas bacterianas. | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| MX389449B (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| JOP20190129B1 (ar) | تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| EA201791937A1 (ru) | Противовоспалительные полипептиды | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| EA202091524A1 (ru) | Ингибиторы рецептора, активируемого протеазой 2 | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| AR106769A1 (es) | Composiciones que comprenden cepas bacterianas | |
| EA202090846A1 (ru) | Новые ингибиторы глутаминазы |